RxDoctor Payments Data

Eleanor Tennyson, MD

Family Medicine · Houston, TXNPI 1407017486

Payments from drug & device makers

$2,483in general payments, 2019–2025

Across 146 payments — averaging $17.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$900
  • AstraZeneca$444
  • Lilly USA, LLC$276
  • Amgen$140
  • Astellas Pharma US Inc$111
  • Boehringer Ingelheim$93
  • plus $518 from 15 others

What the payments were for

  • Food & beverage$2,476100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,483 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$50,377
Medicare patients
97
Services billed
666

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide33$62,043
JardianceEmpagliflozin52$51,166
JanuviaSitagliptin Phosphate32$34,978
XareltoRivaroxaban28$31,807
VascepaIcosapent Ethyl49$31,091
FarxigaDapagliflozin Propanediol34$25,528
EliquisApixaban17$23,220
TradjentaLinagliptin23$21,884
OzempicSemaglutide12$20,142
TrulicityDulaglutide12$19,750
MyrbetriqMirabegron15$14,402
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,837
Icosapent Ethyl16$6,927
Atorvastatin Calcium577$5,708
Albuterol Sulfate HfaAlbuterol Sulfate160$4,714

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$276$81,79445 claims
Boehringer IngelheimJardiance, Tradjenta$93$73,05075 claims
MerckJanuvia$12$34,97832 claims
AstraZenecaFarxiga$444$25,52834 claims
PfizerEliquis$83$23,22017 claims
Novo NordiskOzempic$900$20,14212 claims
Astellas Pharma US IncMyrbetriq$111$14,40215 claims
GSKTrelegy Ellipta$38$8,83713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →